Pharmacist-led Interventions to Improve Medication Use

NCT05346770 | Unknown

• 1 other identifier: TRHC-CS-2021-001
• Study Type: observational
• Target: 25
• Locations: 1 country
• Sites: 1

Brief Summary

The objective of this project is to stimulate identification and report of patient's medical story for whom their clinical conditions beneficiated from pharmacists' interventions based on a medication safety review. Cases will be systematically identified and reported in the scientific (peer review journals) and clinical communities in order to inform and provide better care.

Conditions

Pharmacogenomics; Old Age

Outcome Measures

Primary Outcomes (1)

• Medication safety reviews of patient drug regimen characteristics will be conducted to determine potential drug-drug interactions.

  Medication safety reviews will be conducted and reported using Tabula Rasa Healthcare proprietary software MedWise to assign a Medication Risk Score. This evaluation incorporates over-the-counter medications, herbals, and supplements to illuminate simultaneous, multi-drug interactions. Based on the data, patients are assigned a risk score ranging from 0 to 50, where 0-9 indicates minimal risk, 10-14 indicates low risk, 15-19 indicates intermediate risk, 20-29 indicates high risk, and 30 and above indicates severe risk.

  1 year

Study Arms (1)

Individual Patient

Each case will represent one individual patient and patient case. The cases may not be related and may cover different clinical practice areas.

Behavioral: Behavioral Intervention; Diagnostic Test: Diagnostic Test; Other: Data Analysis

Interventions

Behavioral Intervention BEHAVIORAL

A behavioral intervention could include changing the time of day a drug is taken.

Individual Patient

Diagnostic Test DIAGNOSTIC_TEST

A patient may receive a pharmacogenomic test via cheek swab to find PGx results. This is a benign intervention with little to no risk to the patient.

Individual Patient

Data Analysis OTHER

Medication safety reviews, and retrospective or prospective data analysis may occur as a result of participation in a case study.

Individual Patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient enrolled in a healthcare organization where Tabula Rasa Healthcare provides pharmacy services during the implementation period.

You may qualify if:

• Patients meeting all the following criteria will be considered:
• Patient enrolled in a healthcare organization where TRHC provides pharmacy services during the implementation period.
• Patient (or legal representative) able to understand, and provide informed consent to publish his/her case story.
• Patient's case will provide generalizable knowledge to the existing literature based on direct observation, interview, benign behavioral intervention, or findings from drug regimen or drugs claims data.

You may not qualify if:

• Patients with one of the following criteria will be excluded:
• a) Patient's refusal to participate in a case study

Sponsors & Collaborators

• Tabula Rasa HealthCare: lead

Study Sites (1)

Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute

Orlando, Florida, 32827, United States

Location

Related Links

• Related Info

MeSH Terms

Interventions

Behavior Therapy; Diagnostic Tests, Routine

Intervention Hierarchy (Ancestors)

Psychotherapy; Behavioral Disciplines and Activities; Diagnostic Techniques and Procedures; Diagnosis

Study Officials

• Veronique Michaud, PhD

  TRHC

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 2, 2022
• First Posted: April 26, 2022
• Study Start: January 25, 2022
• Primary Completion: January 24, 2024
• Study Completion: July 24, 2024
• Last Updated: September 2, 2022

Record last verified: 2022-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)